Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued on Wednesday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of NYSE:BTX opened at $7.40 on Wednesday. Brooklyn ImmunoTherapeutics has a 1 year low of $6.66 and a 1 year high of $8.31. The firm has a market capitalization of $435.31 million, a PE ratio of -3.26 and a beta of 4.61. The business’s 50 day moving average price is $0.93 and its 200-day moving average price is $1.04.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.